• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

女性乳腺原位癌。一项全国性前瞻性研究的10年随访结果。

Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.

作者信息

Ottesen G L, Graversen H P, Blichert-Toft M, Christensen I J, Andersen J A

机构信息

Department of Forensic Pathology, University of Copenhagen, Denmark.

出版信息

Breast Cancer Res Treat. 2000 Aug;62(3):197-210. doi: 10.1023/a:1006453915590.

DOI:10.1023/a:1006453915590
PMID:11072784
Abstract

In a Danish nationwide prospective study of in situ carcinoma of the breast, a total of 275 women, treated with excision alone, were registered from 1982 to 1989. The series included 142 cases of ductal carcinoma in situ (DCIS), 100 cases of lobular carcinoma in situ (LCIS), 26 cases of DCIS+LCIS, and seven cases of atypical hyperplasia (AH). Within a median follow-up of 120 months, a crude recurrence rate of 28% (76 cases) was found, of which 53% (40 cases) recurred as invasive carcinomas (IC) and 47% (36 cases) as CIS. CIS recurrences appeared after median 18 months, compared to median 42 months for IC recurrences. No statistical difference was found with respect to development of IC between the three groups of DCIS, DCIS+LCIS, and LCIS. The majority of recurrences were ipsilateral, also for LCIS. Forty four of 49 recurrences following DCIS, and seven of nine recurrences following DCIS+LCIS occurred as local recurrences. Histopathologically, in DCIS a strong association was found between large nuclear size and comedonecrosis. Univariate analysis showed a significant association to recurrence for nuclear size, comedonecrosis, and size of the original lesion. Multivariate analysis showed that only comedonecrosis and size of lesion were independent predictors of recurrence, however, specimen margins were not included in the analysis, as this parameter could not be adequately evaluated in the present series. Nuclear size of original DCIS lesion was related to histologic grade of the IC recurrence. The recurrence rate for DCIS of small nuclear size increased from 6% at five years of follow-up to 16% at 10 years, possibly due to a slower growth rate and a continued but delayed risk. Similarities were found between LCIS and DCIS of small nuclear size, both showing a continued risk and comparable rate of recurrence. Further, progression to IC of similar, highly differentiated type was seen, indicating a linkage between biological behavior of the two histological types.

摘要

在一项丹麦全国性的乳腺原位癌前瞻性研究中,1982年至1989年期间共登记了275例仅接受切除术治疗的女性。该系列包括142例导管原位癌(DCIS)、100例小叶原位癌(LCIS)、26例DCIS+LCIS以及7例非典型增生(AH)。在中位随访120个月时,发现粗复发率为28%(76例),其中53%(40例)复发为浸润性癌(IC),47%(36例)复发为原位癌(CIS)。CIS复发的中位时间为18个月,而IC复发的中位时间为42个月。DCIS、DCIS+LCIS和LCIS三组之间在IC发生方面未发现统计学差异。大多数复发为同侧,LCIS也是如此。DCIS后的49例复发中有44例,DCIS+LCIS后的9例复发中有7例为局部复发。组织病理学上,在DCIS中发现细胞核大小与粉刺样坏死之间存在强关联。单因素分析显示细胞核大小、粉刺样坏死和原发灶大小与复发有显著关联。多因素分析表明,只有粉刺样坏死和病灶大小是复发的独立预测因素,然而,分析中未包括标本切缘,因为在本系列中无法充分评估该参数。原发DCIS病灶的细胞核大小与IC复发的组织学分级有关。细胞核小的DCIS在随访5年时的复发率从6%增加到10年时的16%,这可能是由于生长速度较慢以及持续但延迟的风险。在细胞核小的LCIS和DCIS之间发现了相似之处,两者都显示出持续的风险和相当的复发率。此外,还观察到进展为相似的高分化类型的IC,表明这两种组织学类型的生物学行为之间存在联系。

相似文献

1
Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.女性乳腺原位癌。一项全国性前瞻性研究的10年随访结果。
Breast Cancer Res Treat. 2000 Aug;62(3):197-210. doi: 10.1023/a:1006453915590.
2
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.女性乳腺原位癌。一项临床病理、免疫组织化学及DNA倍体研究。
APMIS Suppl. 2003(108):1-67.
3
Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group.女性乳腺小叶原位癌。一项全国性前瞻性研究的短期结果。丹麦乳腺癌协作组
Am J Surg Pathol. 1993 Jan;17(1):14-21. doi: 10.1097/00000478-199301000-00002.
4
Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.1988 - 2001年原位导管癌和原位小叶癌女性患者发生浸润性乳腺癌的风险
Cancer. 2006 May 15;106(10):2104-12. doi: 10.1002/cncr.21864.
5
Is there a low-grade precursor pathway in breast cancer?乳腺癌是否存在低度恶性前体途径?
Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.
6
Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.乳腺粗针活检中非典型导管增生和小叶原位癌的长期临床随访
Pathology. 2016 Jan;48(1):25-9. doi: 10.1016/j.pathol.2015.11.015. Epub 2015 Dec 14.
7
Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.伴同侧小叶原位癌的导管原位癌患者对侧乳腺癌风险。
Ann Surg Oncol. 2019 Dec;26(13):4317-4325. doi: 10.1245/s10434-019-07796-9. Epub 2019 Sep 24.
8
Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.乳腺小叶原位癌(LCIS):其长期预后与导管原位癌(DCIS)相似吗?200例病例分析。
Radiat Oncol. 2015 May 6;10:110. doi: 10.1186/s13014-015-0379-7.
9
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.167例女性原位乳腺癌——发病率、临床表现、治疗及随访
Eur J Surg Oncol. 1991 Oct;17(5):466-76.
10
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.同时存在的增殖性高危病变对接受保乳治疗的导管原位癌患者同侧乳腺癌复发风险及对侧乳腺癌发生风险的影响。
Cancer. 2006 Jan 1;106(1):42-50. doi: 10.1002/cncr.21571.

引用本文的文献

1
Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.伴同侧小叶原位癌的导管原位癌患者对侧乳腺癌风险。
Ann Surg Oncol. 2019 Dec;26(13):4317-4325. doi: 10.1245/s10434-019-07796-9. Epub 2019 Sep 24.
2
Ductal carcinoma in situ: to treat or not to treat, that is the question.导管原位癌:治疗还是不治疗,这是个问题。
Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6. Epub 2019 Jul 9.
3
Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
用于对存档的、来自高达35年历史的临床福尔马林固定石蜡包埋(FFPE)样本中的微小RNA进行回顾性测序的基于实验室的cDNA文库制备方案的评估与调整。
Int J Mol Sci. 2017 Mar 14;18(3):627. doi: 10.3390/ijms18030627.
4
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).首届乳腺不确定恶性潜能病变(B3病变)国际共识会议
Breast Cancer Res Treat. 2016 Sep;159(2):203-13. doi: 10.1007/s10549-016-3935-4. Epub 2016 Aug 13.
5
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.乳腺导管原位癌的长期预后:一项系统评价、荟萃分析和荟萃回归分析
BMC Cancer. 2015 Nov 10;15:890. doi: 10.1186/s12885-015-1904-7.
6
Molecular drivers of lobular carcinoma in situ.小叶原位癌的分子驱动因素。
Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5.
7
Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?保乳手术后,中度风险的导管原位癌是否需要进行放疗?
Springerplus. 2014 Aug 5;3:405. doi: 10.1186/2193-1801-3-405. eCollection 2014.
8
Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS.E-钙黏蛋白和P120连环蛋白联合免疫染色在鉴别导管原位癌与小叶原位癌中的诊断价值
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2551-7. eCollection 2014.
9
Biofunctional characteristics of in situ and invasive breast carcinoma.原位和浸润性乳腺癌的生物功能特征。
Cell Oncol (Dordr). 2013 Jul;36(4):303-10. doi: 10.1007/s13402-013-0135-7. Epub 2013 Jun 27.
10
Ductal carcinoma in situ: recent advances and future prospects.导管原位癌:最新进展与未来展望
Int J Surg Oncol. 2012;2012:347385. doi: 10.1155/2012/347385. Epub 2012 May 17.